Personalized Pharmacogenomic Testing for Autoimmune Patients

We leverage the advanced PrismRA pharmacogenomic test to provide personalized care for autoimmune patients. This precision screening helps identify which targeted therapies are most likely to work for your specific genetic profile.

PrismRA is a sophisticated blood test that analyzes unique biomarkers to predict whether a patient is likely to respond to Tumor Necrosis Factor (TNF) inhibitor therapies. While these treatments are among the most commonly prescribed options for autoimmune diseases, they are not effective for everyone. Identifying non-responders early allows for a faster, more accurate treatment approach.

This test is ideal for patients diagnosed with rheumatoid arthritis or other complex chronic autoimmune conditions who are currently considering TNF inhibitor therapies. It is also highly valuable for individuals who have experienced limited success with previous standard treatment protocols.

The testing process requires a simple in-office blood draw that undergoes comprehensive genomic analysis. Within days, a detailed report is generated to guide clinical reasoning and help narrow down your therapeutic choices efficiently.

Dr. Baker utilizes her deep experience as a double board-certified internal medicine and rheumatology specialist to carefully evaluate your genomic data within the context of your complete medical history.

We target the correct therapy from the very beginning of your care; this helps you avoid unnecessary medications, reduce healthcare costs, and prevent unwanted side effects.

Instead of waiting months to see if a standard protocol works, precision medicine allows us to focus directly on treatments with a higher statistical likelihood of clinical success.